Abstract: A leaky cable is provided with a linear insulator and a metal layer formed on an outer peripheral surface of the insulator. A slot for leaking electromagnetic waves is formed through the metal layer between an inner peripheral surface and an outer peripheral surface of the metal layer, and the outer peripheral surface of the insulator is formed with unevenness that inhibits misalignment of the slot with respect to the insulator. The method of manufacturing the leaky cable includes forming an insulator composed of thermoplastic resin in a cylindrical shape, roughening an outer peripheral surface of the insulator, forming a metal layer on the outer peripheral surface of the insulator, and forming a slot through the metal layer between an inner peripheral surface and an outer peripheral surface of the metal layer. The slot is configured to leak electromagnetic waves to outside of the metal layer.

Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, an optically active compound thereof, a racemate thereof or a diastereomer mixture thereof has a superior tyrosine-specific protein kinase inhibitory activity and is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of various cancers, psoriasis or diseases caused by arteriosclerosis, and the like.

Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt thereof, a hydrate thereof, a solvate thereof, an optically active compound thereof, a racemate thereof or a diastereomer mixture thereof has a superior tyrosine-specific protein kinase inhibitory activity and is useful as a pharmaceutical agent, particularly as an agent for the prophylaxis or treatment of various cancers, psoriasis or diseases caused by arteriosclerosis, and the like.

Abstract: A Her2 and/or EGFR inhibitor to be administered to a subject determined to show overexpression or activation of Her2 and/or EGFR as a result of a diagnosis of the subject for the expression or activity of Her2 and/or EGFR based on a test for detecting the expression or activity of Her2 and/or EGFR, and a pharmaceutical composition containing the inhibitor.

Abstract: A compound of the formula (I) 1

Abstract: A production method of a magnesium hydroxide solid solution, Mg.sub.1-x M.sup.2+ .sub.x (OH).sub.2 or a resin and/or rubber material having as its effective elements containing said solid solution as its flame retardant, characterized by having M.sup.2+ distributed unevenly in a high concentration in the vicinity of the surface of each crystal, in the magnesium solid represented by the formula Mg.sub.1-x M.sup.2+ .sub.x (OH).sub.2 wherein M.sup.2+ is at least one divalent metal ion selected from the group consisting of Mn.sup.2+, Fe.sup.2+, Ni.sup.2+, Cu.sup.2+, Zn.sup.2+ and x indicates a range of 0.001.ltoreq.x<0.5.

Abstract: Disclosed is a benzoylethylene derivative represented by the following formula (I) or a salt thereof. ##STR1## R.sup.1 to R.sup.5 : a hydrogen atom, --OR.sup.9 (R.sup.9 : a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, etc.), etc.,R.sup.6 : a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, etc.,R.sup.7 : a hydrogen atom, a cyano group, a C.sub.1 -C.sub.5 alkyl group, --SO.sub.q R.sup.15 (q: 0, 1, 2, R.sup.15 : a thienyl group, a phenyl group, etc.) etc.,R.sup.8 : a cyano group, --CR.sup.22 R.sup.23 X (R.sup.22, R.sup.23 : a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, etc., X: --NR.sup.24 R.sup.25 (R.sup.24, R.sup.25 : a C.sub.1 -C.sub.5 alkyl group, etc., an alkylene group by combining, etc.)), etc.The benzoylethylene derivative of the present invention has potent tyrosine kinase inhibiting activity and cancer cell growth inhibiting activity. The tyrosine kinase inhibitor of the present invention is useful as a carcinostatic agent.

Abstract: By hydrating a metal oxide solid solution shown as the following formula (3), wherein an average primary crystal particle diameter is in the range of 1 to 10 .mu.m, in the presence of monocarboxylic acid and/or oxymonocarboxylic acid in aqueous medium,Mg.sub.1-z M.sup.2+.sub.z O (3)in which M.sup.2+ represents at least one divalent metal ion selected from the group consisting of Mn.sup.2+, Fe.sup.2+, Co.sup.2+, Ni.sup.2+, Cu.sup.2+ and Zn.sup.2+, and z is in the range of 0.01.ltoreq.z<0.5, a metal hydroxide solid solution having a high aspect ratio shown as the following formula (1) can be obtained;Mg.sub.1-x M.sup.2+.sub.x (OH).sub.2 (1)in which M.sup.2+ represents at least one divalent metal ion selected from the group consisting of Mn.sup.2+, Fe.sup.2+, Co.sup.2+, Ni.sup.2+, Cu.sup.2+ and Zn.sup.2+, and x is in the range of 0.01.ltoreq.x<0.5, characterized by that a crystal is a hexagonal plate in shape, 0.01 to 0.5 .mu.m in average thickness, 1 to 10 .mu.

Abstract: A flame retardant polyolefin compound having low smoking and toxicity comprising 100 parts by weight of polyolefin resin, 100 to 150 parts by weight of a flame retardant, and 2 to 10 parts by weight of zinc stannate as a flame retardant auxilliary agent. The flame retardant polyolefin compound preferably uses a composite metal hydroxide as the flame retardant.

Abstract: A flame retardant polyolefin composition comprising polofin resin and a flame-retarding component which is prepared by adding 1 to 20 parts by weight of fine carbon powder to 100 parts by weight of composite metal hydroxide expressed by the general formula Mg.sub.1-x M.sup.+2.sub.x (OH).sub.2 in which M.sup.+2 is at least one element selected from the group consisting of bivalent metallic ions Mn.sup.+2, Fe.sup.+2, Co.sup.+2, Ni.sup.+2, Cu.sup.+2 and Zn.sup.+2, and x has a value satisfying 0.001.ltoreq.x.ltoreq.0.9.

Abstract: A pharmaceutical composition which comprises a pharmaceutically effective amount of a compound of the formula ##STR1## wherein R.sup.1 represents a hydrogen atom,R.sup.2 represents --(CH.sub.2).sub.m -Awherein m is an integer of 0 to 3, andA represents pyridyl which is unsubstituted or is substituted by C.sub.1 -C.sub.3 alkyl said alkyl being unsubstituted or substituted by phenyl, and R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 each independently represent a hydrogen atom, a halogen atom, C.sub.1 -C.sub.5 alkyl which is unsubstituted or is substituted with a halogen atom or --OR.sup.13 wherein R.sup.13 represents a hydrogen atom or C.sub.1 -C.sub.5 alkyl which is unsubstituted or is substituted with a halogen atom or phenyl, or when their adjacent substituents are taken together, they represent C.sub.1 -C.sub.3 oxyalkylene having one or two oxygen atoms;or a pharmaceutically acceptable salt thereof, anda pharmaceutically acceptable carrier therefor.

Abstract: Styrene derivatives of the following general formula (I): ##STR1## or pharmaceutically acceptable salts thereof. A pharmaceutical composition useful as anticancer agent, which comprises the above compound as an essential component, is also provided.

Abstract: Novel acyclic terpene compounds useful as intermediates for producing sarcophytol A which have an anti-carcinogenic promotor activity and anti-tumor activity, which compounds are shown by the following general formula (I): ##STR1## [wherein R.sup.1 is a hydrogen atom, 1-alkoxyalkyl group, tetrahydrofuryl group, tetrahydropyranyl group or acyl group; R.sup.2 is a group of formula: --CHO, --CH.sub.2 OR.sup.3 or ##STR2## (wherein R.sup.3 is a hydrogen atom, 1-alkoxyalkyl group, tetrahydrofuryl group, tetrahydropyranyl group or acyl group; and R.sup.4 is C.sub.1 to C.sub.4 alkyl group) with the proviso that R.sup.1 and R.sup.3 do not represent the same substituents simultaneously; when R.sup.1 is a hydrogen atom, R.sup.3 is not acetyl group or tetrahydropyranyl group; and when R.sup.2 is a group of formula: ##STR3## R.sup.1 is not a hydrogen atom).

Abstract: Acyclic terpene compounds useful as intermediates for producing sarcophytol A which have an anti-carcinogenic promotor activity and anti-tumor activity, which compounds are shown by the general formula (I): ##STR1##

Abstract: Acyclic terpene compounds useful as intermediates or producing sarcophytol A which have an anti-carcinogenic promotor activity and anti-tumor activity, which compounds are shown by the general formula (I): ##STR1##

Abstract: Acyclic terpene compounds useful as intermediates for producing sarcophytol A which have an anti-carcinogenic promotor activity and anti-tumor activity, which compounds are shown by the general formula (I): ##STR1##

Abstract: Novel monocyclic terpene derivative of the formula: ##STR1## wherein R is hydrogen atom, trimethylsilyl group or 1-ethoxyethyl group, and novel intermediates therefor. The terpene derivative (I) is a useful intermediate for preparing Sarcophytol A having an anti-carcinogenesis promoter activity and an antitumor activity.

Abstract: Acyclic terpene compounds useful as intermediates for producing sarcophytol A which have an anti-carcinogenic promoter activity and anti-tumor activity, which compounds are shown by the general formula (I): ##STR1##

Abstract: The present invention provides novel acyclic terpenes of the formula: ##STR1## which are useful as intermediates for the industrially advantageous production of sarcophytol A.

Abstract: Conjugated diene compounds of the general formula: ##STR1## which are industrially advantageous intermediates for preparing sarcophytol A useful as an anticarcinogenic promotor or antitumor agent are provided.